Anika Therapeutics
ANIK
152 hedge funds and large institutions have $475M invested in Anika Therapeutics in 2015 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 63 increasing their positions, 43 reducing their positions, and 10 closing their positions.
150% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 10
101% more call options, than puts
Call options by funds: $2.48M | Put options by funds: $1.24M
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
47% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 43
19% more capital invested
Capital invested by funds: $398M → $475M (+$77.1M)
10% more funds holding
Funds holding: 138 → 152 (+14)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HP
HealthInvest Partners
Stockholm,
Sweden
|
+$12.9M |
| 2 |
NI
Numeric Investors
Boston,
Massachusetts
|
+$6.44M |
| 3 |
CIM
Calvert Investment Management
Bethesda,
Maryland
|
+$2.73M |
| 4 |
SGAM
Smith Group Asset Management
Dallas,
Texas
|
+$2.66M |
| 5 |
Renaissance Technologies
New York
|
+$2.27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCP
Lombardia Capital Partners
Pasadena,
California
|
-$15.9M |
| 2 |
BTW
Boston Trust Walden
Boston,
Massachusetts
|
-$7.19M |
| 3 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
-$5.75M |
| 4 |
TSW
Thompson Siegel & Walmsley
Richmond,
Virginia
|
-$3.92M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$3.92M |
ANIK Hedge Fund Activity: Q4 2015 in Review
152 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in Anika Therapeutics (ANIK) for Q4 2015, worth a combined $475M — up 19% from $398M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new ANIK positions and 10 closed out — a net gain of 15 holders — while 63 added to existing stakes and 43 trimmed.
The largest buyer was HealthInvest Partners, adding an estimated $12.9M. The largest seller was Lombardia Capital Partners, cutting an estimated $15.9M.
- 152 institutional investors held Anika Therapeutics (ANIK) as of Q4 2015, up from 138 in Q3 2015.
- Funds reported $475M of Anika Therapeutics stock for Q4 2015, up 19% quarter-over-quarter.
- 25 funds opened new Anika Therapeutics positions in Q4 2015 and 10 closed out, a net change of +15 holders.
- The largest Anika Therapeutics buyer in Q4 2015 was HealthInvest Partners, an estimated $12.9M added.
- The largest Anika Therapeutics seller in Q4 2015 was Lombardia Capital Partners, an estimated $15.9M sold.
Based on aggregated 13F filings for Q4 2015.